A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C

Publication | Closed Access

DOI

204

Citations

References

2007

Year

Antonio Ojea, José Luís Nogueira, Eduardo Solsona, Nicolás Flores, J.M. Fernández Gómez, Jesús Rodríguez Molina, V. Chantada, José Emilio Camacho, Luis Martínez‐Piñeiro, Rafael Rodríguez,

European Urology

UrologySurgical OncologyGenitourinary CancerMedicineVersus Mitomycin CLow-dose Bacillus Calmette-guerinCancer TreatmentOncologyRadiation Oncology